FT23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 8, 2012, Pages 650-656

  Tan, Sih Min ^a,e   Zhang, Yuan ^a   Wang, Bing ^b   Tan, Christina Y R ^a   Zammit, Steven C ^d   Williams, Spencer J ^d   Krum, Henry ^b   Kelly, Darren J ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c Fibrotech Therapeutics Pty Ltd   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Diabetic cardiomyopathy; Diastolic dysfunction; Fibrosis; Transforming growth factor

Indexed keywords

CARDIOVASCULAR AGENT; FT23; STREPTOZOCIN; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; FIBROBLAST; HEART FUNCTION; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; MALE; MITRAL VALVE; NONHUMAN; RAT; STREPTOZOCIN DIABETES;

ANIMALS; ANIMALS, NEWBORN; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CAFFEIC ACIDS; COLLAGEN; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; ECTODYSPLASINS; EXTRACELLULAR MATRIX; FEMALE; FIBRINOLYTIC AGENTS; FIBROBLASTS; FIBROSIS; HETEROZYGOTE; IMMUNOHISTOCHEMISTRY; LUNG; MYOCARDITIS; MYOCARDIUM; ORTHO-AMINOBENZOATES; RATS; RATS, INBRED STRAINS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84864300437     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2012.05726.x     Document Type: Article

References (22)

1. Mahgoub M, Abd-Elfattah A. Diabetes mellitus and cardiac function. Mol. Cell. Biochem. 1998; 180: 59-64.
2. Mifsud S, Kelly D, Qi W et al. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron Physiol. 2003; 95: 83-91.
3. Kelly DJ, Zhang Y, Connelly K et al. Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 2007; 293: H2860-9.
4. Holmes D, Fitzgerald P, Goldberg S et al. The PRESTO (Prevention of Restenosis with Tranilast and its Outcomes) protocol: A double-blind, placebo-controlled trial. Am. Heart J. 2000; 139: 23-31.
5. Zammit SC, Cox AJ, Gow RM et al. Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates. Bioorg. Med. Chem. Lett. 2009; 19: 7003-6.
6. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int. 1998; 54: 343-52.
7. Connelly KA, Kelly DJ, Zhang Y et al. Functional, structural and molecular aspects of diastolic heart failure in the diabetic ((mRen-2)27 rat. Cardiovasc. Res. 2007; 76: 280-91.
8. Wang BH, Bertuci M, Ma JY, Adrahtas A, Cheung RY, Krum H. Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone. Clin. Exp. Pharmacol. Physiol. 2010; 37: 912-18.
9. Phrommintikul A, Tran L, Kompa A et al. Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2008; 294: H1804-14.
10. Whitworth C, Fleming S, Kotelevtsev Y et al. A genetic model of malignant phase hypertension in rats. Kidney Int. 1995; 47: 529-35.
11. Kelly DJ, Wilkinson-Berka JL, Gilbert RE. Progressive diabetic nephropathy in the Ren-2 rat. Am. J. Physiol. Renal Physiol. 2007; 292: F1662.
12. Martin J, Kelly DJ, Mifsud SA et al. Tranilast attenuates cardiac matrix deposition in experimental diabetes: Role of transforming growth factor-β. Cardiovasc. Res. 2005; 65: 694-701.
13. Connelly KA, Prior DL, Kelly DJ, Feneley MP, Krum H, Gilbert RE. Load-sensitive measures may overestimate global systolic function in the presence of left ventricular hypertrophy: A comparison with load-insensitive measures. Am. J. Physiol. Heart Circ. Physiol. 2006; 290: H1699-705.
14. Junqueira L, Bignolas G, Brentani R. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem. J. 1979; 11: 447-55.
15. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immun. 2000; 1: 510-14.
16. Fein F, Sonnenblick E. Diabetic cardiomyopathy. Cardiovasc. Drugs Ther. 1994; 8: 65-73.
17. Holman R, Paul S, Bethel M, Neil H, Matthews D. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N. Engl. J. Med. 2008; 359: 1565-76.
18. Holman R, Paul S, Bethel M, Matthews D, Neil H. 10-Year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008; 359: 1577-89.
19. Leite-Moreira AF. Current perspectives in diastolic dysfunction and diastolic heart failure. Heart 2006; 92: 712-18.
20. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II. Causal mechanisms and treatment. Circulation 2002; 105: 1503-8.
21. Van Linthout S, Riad A, Dhayat N et al. Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia 2007; 50: 1977-86.
22. Tesch GH. Role of macrophages in complications of type 2 diabetes. Clin. Exp. Pharmacol. Physiol. 2007; 34: 1016-19.